喉鳞癌组织两种P糖蛋白单克隆抗体的检测

Detection of P-glycoprotein in squamous cell carcinoma of larynx

为了解喉鳞癌的多药耐药性，以期提高综合治疗中化疗的效果，采用免疫组化技术对未经任何治疗的喉鳞癌患者在手术中取出的新鲜肿瘤组织进行了Ｐ糖蛋白（Ｐ－ｇｌｙｃｏｐｒｏｔｅｉｎ，ＰＧＰ）单克隆抗体ＪＳＢ１及单克隆抗体Ｃ２１９的检测。对比了肿瘤组织分化程度、肿瘤大小及有无淋巴结转移与ＰＧＰ表达阳性之间的关系。结果发现，单抗ＰＧＰＪＳＢ１的阳性率为６５．２％（ｎ＝２３），而单抗Ｃ２１９检测的６例ＰＧＰ均为阴性，与分化无关，与肿瘤大小、转移亦无相关性。多药耐药因子的表达及其对于化疗的指导作用尚需进一步加以研究。建议当喉癌患者接受化学疗法时，可同时采用三苯氧胺（ＴＡＭ）为耐药调节剂以便提高治疗效果。

The multidrug resistance (MDR) of malignant tumor is a troublesome problem in the chemotherapy. One established mechanism of multidrug resistance is elevated expression of the Pglycoprotein (PGP). JSB1 (which is a special monoclonal antibody of human MDR, PGP) was used to examine the expression of PGP by immunohistochemistry in 23 specimens of squamous cell carcinoma of larynx. The expression of JSB1 in 10 normal laryngeal tissue specimens was also studied, no positive result was found. Of the 23 laryngeal cancer specimens, positive reaction to JSB1 was showed in 15, and there was no relationship between the positive expression, and the tumor differentiation, T staging and lymphnode metastasis. However, by using another newly developed monoclonal antibody C219, a different result was obtained from specimens of the same patients.